Bart De Strooper, MD, PhD, UK Dementia Research Institute and University College London, London, UK, discusses the different avenues of research that the UK Dementia Research Institute is exploring, including neurodegenerative diseases other than Alzheimer’s disease. For all neurodegenerative diseases and amyotrophic lateral sclerosis (ALS), the development of new targets starts with researching disease mechanisms. Once targets within these mechanisms are identified, they can be translated into treatments or biomarkers. In order to achieve this, collaboration with the industry and clinic is imperative. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Consultant for EISAI and Janssen Pharmaceutics. Research funding from Janssen Pharmaceutics.